Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-β
AP Jiménez-Uribe, T Gomez-Sierra, OE Aparicio-Trejo… - Cellular …, 2021 - Elsevier
The fibrotic process could be easily defined as a pathological excess of extracellular matrix
deposition, leading to disruption of tissue architecture and eventually loss of function; …
deposition, leading to disruption of tissue architecture and eventually loss of function; …
Targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis
H Ma, S Liu, S Li, Y **a - Frontiers in Pharmacology, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin
that usually results in death from secondary respiratory failure within 2–5 years of diagnosis …
that usually results in death from secondary respiratory failure within 2–5 years of diagnosis …
Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis
WS Bowman, CA Newton, AL Linderholm… - The Lancet …, 2022 - thelancet.com
Background Progressive fibrosing interstitial lung disease (ILD) is characterised by
parenchymal scar formation, leading to high morbidity and mortality. The ability to predict …
parenchymal scar formation, leading to high morbidity and mortality. The ability to predict …
The regenerative power of stem cells: treating bleomycin-induced lung fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with no known
cure, characterized by the formation of scar tissue in the lungs, leading to respiratory failure …
cure, characterized by the formation of scar tissue in the lungs, leading to respiratory failure …
Update in interstitial lung disease 2020
AJ Podolanczuk, AW Wong, S Saito… - American Journal of …, 2021 - atsjournals.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–
induced coronavirus disease (COVID-19) dominated the year 2020. Initial reports of the long …
induced coronavirus disease (COVID-19) dominated the year 2020. Initial reports of the long …
Epithelial–mesenchymal transition: a major pathogenic driver in idiopathic pulmonary fibrosis?
Medicina | Free Full-Text | Epithelial–Mesenchymal Transition: A Major Pathogenic Driver in
Idiopathic Pulmonary Fibrosis? Next Article in Journal Vertical Bone Gain after Sinus Lift …
Idiopathic Pulmonary Fibrosis? Next Article in Journal Vertical Bone Gain after Sinus Lift …
The ANGPTL4-HIF-1α loop: a critical regulator of renal interstitial fibrosis
Y Li, S Chen, Q Yang, X Liu, W Zhou, T Kang… - Journal of translational …, 2024 - Springer
Background Renal interstitial fibrosis (RIF) is a progressive, irreversible terminal kidney
disease with a poor prognosis and high mortality. Angiopoietin-like 4 (ANGPTL4) is known …
disease with a poor prognosis and high mortality. Angiopoietin-like 4 (ANGPTL4) is known …
Novel mediators of idiopathic pulmonary fibrosis
Fibrosis involving the lung may occur in many settings, including in association with known
environmental agents, connective tissue diseases, and exposure to drugs or radiation …
environmental agents, connective tissue diseases, and exposure to drugs or radiation …
Understanding idiopathic pulmonary fibrosis-clinical features, molecular mechanism and therapies
Idiopathic pulmonary fibrosis (IPF) is a chronic lung fibrosing disease with high prevalence
that has a prognosis worse than many cancers. There has been a recent influx of new …
that has a prognosis worse than many cancers. There has been a recent influx of new …
Molecular regulation of skeletal muscle growth and organelle biosynthesis: practical recommendations for exercise training
R Solsona, L Pavlin, H Bernardi… - International Journal of …, 2021 - mdpi.com
The regulation of skeletal muscle mass and organelle homeostasis is dependent on the
capacity of cells to produce proteins and to recycle cytosolic portions. In this investigation …
capacity of cells to produce proteins and to recycle cytosolic portions. In this investigation …